MetaVia

MetaVia EBITDA per Employee

The EBITDA per Employee of MetaVia (MTVA) as of Oct 30, 2026 is -1.52 M USD. In the previous year, EBITDA per Employee was -3.20 M USD — a change of -52.42% (higher).

EBITDA per Employee

-1.52 MUSD

YoY

-52.42%

Last updated:

EBITDA per Employee of MetaVia is 2025 -1.52 M USD. EBITDA per Employee of MetaVia was 2024 -3.20 M USD. It decreases by -52.42% higher compared to the previous year.

The MetaVia EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-1.72 M USD
Jan 1, 2019
-2.24 M USD
Jan 1, 2020
-3.30 M USD
Jan 1, 2021
-1.70 M USD
Jan 1, 2022
-2.18 M USD
Jan 1, 2023
-1.77 M USD
Jan 1, 2024
-3.20 M USD
Jan 1, 2025
-1.52 M USD
The MetaVia EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.52 MUSD-52.42%
-3.20 MUSD+81.35%
-1.77 MUSD-19.06%
-2.18 MUSD+28.30%
-1.70 MUSD-48.52%
-3.30 MUSD+47.28%
-2.24 MUSD+30.29%
-1.72 MUSD-53.25%
-3.68 MUSD+125.39%
-1.63 MUSD+81.97%
-897,333.33USD+2,936.09%
-29,555.56USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

EBITDA per Employee of MetaVia is -1.52 M USD in 2025.

EBITDA per Employee of MetaVia changed from -3.20 M USD to -1.52 M USD, representing a -52.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee MetaVia since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's MetaVia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — MetaVia

All Key Metrics — MetaVia